Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 138Lymphoma 35Leukemia 34Multiple Myeloma 33Leukemia, Lymphocytic, Chronic, B-Cell 32Neoplasms, Plasma Cell 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Monoclonal Gammopathy of Undetermined Significance 29Lymphoma, Non-Hodgkin 29Lymphoma, Mantle-Cell 29Lymphoma, Large-Cell, Immunoblastic 29Lymphoma, Large B-Cell, Diffuse 29Lymphoma, Follicular 29Burkitt Lymphoma 28Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, B-Cell, Marginal Zone 27Hodgkin Disease 27Myelodysplastic Syndromes 26Immunoglobulin Light-chain Amyloidosis 26Myeloproliferative Disorders 25Lymphoma, T-Cell, Cutaneous 25Immunoblastic Lymphadenopathy 25Waldenstrom Macroglobulinemia 24Lymphoma, Large-Cell, Anaplastic 24Leukemia, Myeloid, Acute 24Uterine Cervical Neoplasms 22Primary Myelofibrosis 22Leukemia, Large Granular Lymphocytic 22Leukemia, Hairy Cell 22Thrombocythemia, Essential 21

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Primary Condition: Advanced Tumors × Other neoplasm × Clear all
NCT05650203 2023-04-05

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Withdrawn
Other neoplasm

Primary Condition: Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡